Respiratory viral infection occurred in 51% of pediatric lung transplant recipients but was not associated with the development of chronic allograft rejection (p=0.25) or death.
Cohort (n=55)
Does respiratory viral infection impact chronic allograft rejection or mortality in pediatric lung transplant recipients?
Respiratory viral infections are common after pediatric lung transplantation but do not appear to increase the risk of chronic allograft rejection or mortality.
valor p: p=0.25
To evaluate the epidemiology and to investigate the impact of RVI on chronic allograft rejection after pediatric lung transplantation, a retrospective study of pediatric lung transplant recipients from 2002 to 2007 was conducted. Association between RVI and continuous and categorical risk factors was assessed using Wilcoxon rank-sum tests and Fisher's exact tests, respectively. Association between risk factors and outcomes were assessed using Cox proportional hazards models. Fifty-five subjects were followed for a mean of 674 days (range 14-1790). Twenty-eight (51%) developed 51 RVI at a median of 144 days post-transplant (mean 246; range 1-1276); 41% of infections were diagnosed within 90 days. Twenty-five subjects developed 39 LRI, and eight subjects had 11 URI. Organisms recovered included rhinovirus (n = 14), adenovirus (n = 10), parainfluenza (n = 10), influenza (n = 5), and RSV (n = 4). Three subjects expired secondary to their RVI (two adenovirus, one RSV). Younger age and prior CMV infection were risks for RVI (HR 2.4 95% CI 1.1-5.3 and 17.0; 3.0-96.2, respectively). RVI was not associated with the development of chronic allograft rejection (p = 0.25) or death during the study period. RVI occurs in the majority of pediatric lung transplant recipients, but was not associated with mortality or chronic allograft rejection.
Liu et al. (Fri,) conducted a cohort in Pediatric lung transplantation (n=55). Respiratory viral infection vs. No respiratory viral infection was evaluated on Chronic allograft rejection (p=0.25). Respiratory viral infection occurred in 51% of pediatric lung transplant recipients but was not associated with the development of chronic allograft rejection (p=0.25) or death.